UY40815A - Bloqueadores de canales de sodio - Google Patents

Bloqueadores de canales de sodio

Info

Publication number
UY40815A
UY40815A UY0001040815A UY40815A UY40815A UY 40815 A UY40815 A UY 40815A UY 0001040815 A UY0001040815 A UY 0001040815A UY 40815 A UY40815 A UY 40815A UY 40815 A UY40815 A UY 40815A
Authority
UY
Uruguay
Prior art keywords
sodium channel
channel blockers
modulate
disorders
treating
Prior art date
Application number
UY0001040815A
Other languages
English (en)
Inventor
Xiang Gao
Nichola Smith
Robert Francis Day
Adam Friedman
Hatice Belgin Gulgeze Efthymiou
Tyler Harrison
Jay Francis Larrow
Yunshan Peng
Haihao Tang
Yanxiang Wu
Sandra Marie King
Sii Hong Lau
Tajesh Pate
Doré Michael
Michael Gampe Christian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY40815A publication Critical patent/UY40815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)

Abstract

La presente divulgación se refiere a compuestos de sulfonamida, a su uso para modular el canal de sodio Nav1.5, y a métodos para tratar o prevenir enfermedades, trastornos o afecciones usando los mismos.
UY0001040815A 2023-07-07 2024-07-05 Bloqueadores de canales de sodio UY40815A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2023106400 2023-07-07

Publications (1)

Publication Number Publication Date
UY40815A true UY40815A (es) 2025-01-15

Family

ID=94214640

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040815A UY40815A (es) 2023-07-07 2024-07-05 Bloqueadores de canales de sodio

Country Status (16)

Country Link
US (2) US20250034108A1 (es)
EP (1) EP4739669A1 (es)
JP (1) JP2026524110A (es)
KR (1) KR20260035224A (es)
CN (1) CN121548572A (es)
AR (1) AR133184A1 (es)
AU (1) AU2024296422A1 (es)
CL (1) CL2026000001A1 (es)
CO (1) CO2025019045A2 (es)
CR (1) CR20250551A (es)
DO (1) DOP2025000336A (es)
IL (1) IL325153A (es)
MX (1) MX2026000100A (es)
TW (1) TW202502310A (es)
UY (1) UY40815A (es)
WO (1) WO2025011450A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021941A2 (en) * 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
ES2586213T3 (es) * 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
WO2017201468A1 (en) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP3551626B1 (en) * 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
TW202003490A (zh) * 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US10981905B2 (en) * 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN110885319B (zh) * 2018-09-10 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Also Published As

Publication number Publication date
AR133184A1 (es) 2025-09-03
AU2024296422A1 (en) 2025-12-18
WO2025011450A1 (en) 2025-01-16
EP4739669A1 (en) 2026-05-13
DOP2025000336A (es) 2026-03-15
CR20250551A (es) 2026-01-19
CN121548572A (zh) 2026-02-17
CL2026000001A1 (es) 2026-04-06
WO2025011450A9 (en) 2026-01-15
US20250034108A1 (en) 2025-01-30
TW202502310A (zh) 2025-01-16
CO2025019045A2 (es) 2026-01-23
KR20260035224A (ko) 2026-03-12
JP2026524110A (ja) 2026-07-17
IL325153A (en) 2026-02-01
US20260167617A1 (en) 2026-06-18
MX2026000100A (es) 2026-03-02